Article · 19 Jun 2026
Conference abstract
Risk management life cycle approach - key points
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The health authoritiesâ?? activities are targeting public health protection from the harm of used medicines, emphasizing their role in medicines risk assessment. Such achievement requires optimization of their collaboration with industry, addressing criticalities. The interactions with the involved stakeholders have a pivotal role where transparency during assessment of medicinesâ?? benefitâ??risk profile throughout its life cycle should be ensured. Structured benefit/risk assessment framework earlier in drug development is challenging for medicinal products approval that necessitate positive benefit-risk balance parameters. At the end, the key question is â??Do the health authoritiesâ?? interactions with patients and healthcare professionals have a beneficial impact on the taken decisionâ?�?
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Essam Ghanem”

